The prophylactic use of T cell depletion (TCD) strategies for the prevention of graft-versus-host disease (GVHD) following allogeneic stem cell transplantation remains widespread. Initial reports of high incidence of graft rejection after TCD BMT led to a move away from this approach but improved conditioning regimens have reduced this risk substantially. The use of TCD has also been associated with higher relapse risk post-BMT although the success of donor leukocyte infusion (DLI) as treatment for relapse has reduced this problem, especially in chronic myeloid leukaemia (CML). Currently the use of TCD BMT is increasing particularly due to the relative increase in BMT from non-related donors for whom TCD is the optimal GVHD prophylaxis. However, doubts remain over the long-term effect on the reconstituted immune system of recipients of TCD BMT, particularly in adult recipients. In this study we have undertaken a detailed sequential analysis in 23 patients who received allo-grafts from HLA-identical sibling donors after high-dose chemo/radiotherapy for acute or chronic leukaemia. Of these patients, 11 received non-manipulated grafts, five received 'partially TCD' (PTCD) and a further seven received 'fully TCD' (FTCD) bone marrow. T cell depletion was performed ex vivo by Campath-1M plus autologous serum as a source of complement. Partial TCD describes grafts with a T cell reduction of 1-2 log. Full TCD refers to grafts with a reduction of Ͼ2.5 log. The decision regarding the optimal degree of TCD was clinical and was based upon the perceived relative risk of relapse based upon the disease and remission status. All patients were monitored for up to 12 months post-BMT with regard to reconstitution of T and NK cell subsets. T cell depletion at either level was associated with a slower recovery of CD4 cells. This was most marked in the FTCD recipients and lasted throughout the period of study. CD8 cell recovery was also slower in the TCD recipients but this normalised throughout the 12 months post-BMT. The ratio of CD45RA + :CD45RO + increased in all recipients after month 3. This suggests that a degree of extra-thymic T cell maturation can occur in recipients of allogeneic BMT. NK cell recovery was more rapid in the TCD recipients and these differences were maintained throughout the first year.
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It was established as early as 1968 that acute graft-versushost disease (GVHD) is mediated by lymphocytes 1 and could be prevented with anti-lymphocyte globulin 2 and a variety of methods have subsequently been employed in both animal models and in the clinical setting to achieve this. In the mid-1970s discontinuous density gradients were used to remove mature lymphocytes from donor mouse bone marrow in allogeneic transplant experiments. These depletions prevented all evidence of GVHD and demonstrated that acute GVHD is mediated by T lymphocytes. This led to clinical trials of T cell depletion (TCD) regimens. [3] [4] [5] [6] That TCD could prevent GVHD was accepted in the early 1980s but it soon became apparent that this beneficial effect was countered by a concomitant loss of suppression of residual host immunity, as well as the anti-leukaemic benefit of the donor T cells, leading to a higher rate of graft rejection and/or leukaemia relapse. Successful use of TCD requires establishment of an appropriate balance between the residual immune response of the recipient, which can be achieved by appropriate conditioning, and the adjustment of the T cell content of the donor bone marrow.
Since the late 1970s we have used a variety of strategies for in vivo and ex vivo TCD of donor marrow prior to allogeneic transplantation including a cocktail of three locally produced mAbs: anti-CD6, anti-CD7 and anti-CD8; 7 a ricin-conjugated anti-CD5; 6 as well as Campath-1M. In this study we have used Campath-1M (anti-CDw52) for ex vivo TCD. This is a rat monoclonal IgM reactive with T, B and NK cells. 8 In a previous study of a similar group of patients with AML in 1st CR having HLAmatched sibling donor transplants at our centre we saw no evidence of severe acute GVHD, three cases of grade I acute and one incident of limited chronic GVHD. The relapse rate in this group is 14%. 7 Thus, TCD BMT after appropriate conditioning can prevent GVHD without loss of GVL. However, the question of the effect on immune reconstitution remains. Studies from our group and others during the 1980s suggested that, although delayed, immune reconstitution was normal after TCD BMT. Helper T cell function as determined by the ability to promote immunoglobulin synthesis has been reported to return early after TCD BMT 9 although plasma cell activity can be delayed for up to a year after transplant. 9, 10 Given that many of the recipients of TCD BMT are adult and consequently are assumed to have little or no thymic activity there has been much speculation about the diversity of the T cell repertoire post transplant. It has been shown that the peripheral blood T cells in long-term survivors of non-TCD allogeneic BMT are oligoclonal in nature and this has been taken as evidence that these cells have derived from mature T cells within the graft. 11 Consequently, it has been suggested that the removal of T cells from allo-grafts will restrict the repertoire further, leading to a degree of immune incompetence post transplant. However, extra-thymic T cell maturation can occur 12 and this may lead to normal T cell reconstitution post-TCD BMT.
In this study we have followed 23 recipients of allogeneic BMT from HLA-identical sibling donors for up to 12 months post transplant. Of these, 11 received nonmanipulated grafts, five received grafts after T cell reduction of 1-2 log and the remaining seven received grafts following T cell depletion of Ͼ2 logs. Patients were comprehensively monitored for reconstitution of T and natural killer (NK) cell subsets weekly from week +3 for 3 months and then monthly until month 12.
Materials and methods
All patients undergoing allogeneic BMT from HLA-identical sibling donors for haematopoietic reconstitution following high-dose chemotherapy and radiotherapy for haematological malignancy were enrolled in the study after informed consent. Patient demographics are detailed in Table 1 . All patients received cyclophosphamide (60 mg/kg/day; 2 days) and total body irradiation (750 Gy, fast rate 15 cGy/min, single fraction). No patients received Campath-1G as part of their conditioning regimen. Donor bone marrow was processed to a mononuclear cell fraction in a closed system (Cobe 2991, Zaventem, Belgium) and either infused immediately or T cell depleted to the planned level of T cell content and infused within 6 h. T cell depletion was by complement-mediated lysis. Briefly, the proportion of T cells in the donor marrow was determined by flow cytometry using anti-CD3-FITC monoclonal antibody (Becton Dickinson, Oxford, UK) and absolute mononuclear cell counts were measured by a particle counter (Coulter Z-1, Luton, UK). Combination of the results allowed the calculation of the absolute T cell content of the donor bone marrow. The volume of bone marrow containing the appropriate T cell dose for re-infusion was removed from each harvest and the residue incubated with Campath-1M. Donor serum was used as the source of complement.
The degree of T cell depletion in the Campath-1M-treated bone marrow was assessed in a sample of the treated harvest by flow cytometry using anti-CD3 and the vital dye propidium iodide (5 g/ml; Sigma, Poole, UK). The proportion of live CD3+ve T cells was determined by propidium iodide exclusion. Samples were simultaneously assessed for residual Campath-1M binding to CD3 + cells using anti-rat IgM PE. T cells which remained viable after ex vivo Campath-1M but which continued to bind the rat monoclonal antibody were considered to be part of the depleted fraction since lysis was likely to occur in vivo following re-infusion. The final product was a combination of the non-depleted and depleted fractions, adjusted to achieve the desired T cell content.
The degree of T cell depletion was a clinical decision made with respect to the perceived likelihood of disease recurrence. 'Partial' TCD was determined as 1-2 log reduction in total CD3+ve T cells; 'full' TCD represented a reduction of greater than 2 log as determined by the flow cytometric method. In general, 'good'-risk patients received fully TCD grafts while those at high risk of relapse received non-or partially depleted bone marrow. This differential risk led to greater attrition in the non-TCD group, with 12 month survival of 36% compared with 83% in the fully TCD group. However, the larger starting population in the non-TCD group ensured that similar numbers of patients were assessed in each group at each time-point.
Patients were followed at least 3 ×/week after transplant with respect to white blood cell count and leukocyte differential until engraftment. After 3 weeks the EDTA-preserved samples were additionally assayed for lymphocyte phenotypes by a lysed whole blood technique and threecolour flow cytometry. All leukocyte counts and differentials were performed within 6 h of venepuncture whilst immunophenotyping was performed within 24 h. The combinations of monoclonal antibodies (mAbs) are listed in Table 2 . Monoclonal antibodies were conjugated with FITC, PE or PerCp. All were supplied by Becton Dickinson Immunocytometry Systems (Oxford, UK). Labelling was by a standard lysed whole blood method with a proprietary red cell lysis buffer (FACSlyse; Becton Dickinson). All samples were analysed by flow cytometry (FACScan; Becton Dickinson Immunocytometry Systems) within 4 h of preparation. Lymphocytes were isolated by electronic gating on the basis of forward and side angle light scatter signals and at least 5000 events collected as list mode data (Lysis II; Becton Dickinson Immunocytometry Systems). Table 2 Monoclonal antibody combinations
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Phenotyping data were analysed in an interrelational threecolour system (Paint-a-Gate Plus; Becton Dickinson Immunocytometry Systems). Statistical analysis was performed on the means and standard deviations of each comparable distribution by nonpaired Student's t-test after initial analysis of variance by F test. Homoscedastic distributions were compared by conventional Student's t-test while those of unequal variance were compared by Snedecor's modified t-test.
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Results
Lymphocyte engraftment
The rate of lymphocyte engraftment followed a broad distribution in each of the three groups of patients. The absolute peripheral blood lymphocyte count can be used as a broad indicator of lymphocyte engraftment and the mean value for all patients during the initial 3 months post BMT was 0.52 ϫ All patient groups showed similar mean absolute lymphocyte counts at the 3 and 6 month time-points although the fully TCD group showed a trend towards lower absolute counts which was not statistically significant. In contrast, the mean absolute lymphocyte counts in the recipients of non-TCD or partial TCD were significantly higher than that of the fully TCD group (1.33 ϫ 10 9 /l vs 2.23 ϫ 10 9 /l vs 0.62 ϫ 10 9 /l, respectively) (P Ͻ 0.02).
T lymphocyte reconstitution
TCD, whether full or partial, was associated with a slower recovery of CD4 cells than non-TCD transplant. In the non-TCD recipients the absolute number of CD4 cells rose steadily after BMT and in the final period of analysis had reached the lower end of the normal adult range, although even by 6 months after transplant it had not exceeded the proportion of CD8 cells. In contrast, although the CD4 cell level rose in the two TCD groups during the period of study, neither reached the lower level of normal at any time during the 12 month period. Analysis between 1-3, 3-6 and beyond 6 months post-transplant showed a consistently lower CD4 cell incidence in the recipients of TCD marrow than in recipients of non-manipulated grafts at each timepoint. The CD4 reconstitution in the recipients of fully TCD grafts was significantly slower than either the partial or non-TCD groups at 6 months (P Ͻ 0.001 for both) (Figure 1a ). This was also true of the period between 6 and 12 months post-BMT although at this time the recipients of partial TCD grafts showed lower CD4 levels than the non-TCD recipients (P Ͻ 0.05).
CD45RA expression is a phenotypic marker of immune naivity since it is lost upon activation. The proportion of CD4 cells expressing CD45RA fell consistently in the fully TCD recipients at each time-point after BMT. In contrast, while there were no significant differences between the relative proportions of CD45RA + CD4 cells in the three groups in the first 3 months after BMT, both the partial TCD and non-TCD showed a significant increase in CD45RA+ve at the further time-point (P Ͻ 0.01) ( Figure  1b ). Although these changes were statistically significant, they represented small increases in the relative proportions since the majority (78-98%) of the CD4 cells in all groups of patients were CD45RAϪve/CD28+ve (Figure 1c ). CD8 T cell reconstitution was more rapid than that of CD4 in all groups and was within the normal adult range within 3 months (Figure 2a) . However, the recipients of fully TCD grafts showed significantly lower absolute numbers of CD8 cells in the final period of study due to the low absolute lymphocyte count described above. In addition, despite similar total lymphocyte counts between groups at the 3 month time-point, the absolute number and proportion of CD8 cells was significantly lower at 3 months post BMT in the fully TCD patients as compared with both the partial and non-TCD recipients (P Ͻ 0.001). At this time, all three groups showed low incidence of CD45RA + /CD8+ve cells and this proportion rose at each subsequent time-point in each group. These two observations suggest that the CD8 cells arising early after BMT are mature cells included in the graft. The subsequent rise in CD45RA
+ cells within the CD8 cell subset was accompanied by a concomitant fall in the expression of CD28 (Figure 2c ) in all patient groups. The fall was most marked in the two TCD groups and was significantly lower in these than in the non-TCD recipients (P Ͻ 0.001). The initial incidence of CD28 + cells within the CD8 subset was within the normal adult range in all three groups, further supporting the suggestion that these cells were transplanted with the graft. By the latter 6 months this had fallen below the normal range in the recipients of TCD transplants (Figure 2c ).
All three groups showed very high levels of CD8 activation as measured by HLA-DR expression throughout the period of study. There were no significant differences between the three groups in the first 6 months although the non-TCD and partial TCD groups showed a trend towards decreasing CD8 cell activation while the level was maintained in the fully TCD group (Figure 2d ). In the latter 6 months the proportion of CD8 cells which were activated in the fully TCD group was significantly higher than in the partial and non-TCD patients (P Ͻ 0.02 and P Ͻ 0.001, respectively).
CD57 expression on CD8 cells was consistently in the upper normal range for all groups and showed a trend to increasing with time post BMT (Figure 2e) . The distributions were broad in all patient groups and showed no significant differences. Natural killer cell reconstitution was swift in all groups post-BMT (Figure 3a ) and, as a proportion of the total lymphocytes, exceeded the upper limit of normal within 3 months in the fully TCD group (Figure 3c ). All three groups behaved identically with respect to NK cell reconstitution and the relative proportion of CD56+ve cells fell consistently with time although the proportion of NK cells in the fully TCD group remained significantly higher in the fully TCD group than in either of the other groups at all time-points (P Ͻ 0.001). This high relative proportion within the total lymphocyte population in the fully TCD group meant that the absolute number of NK cells per mm 3 in this group was not significantly different from those of either the partial or non-TCD groups The early NK cell expansion seen in the fully TCD group was predominantly within the CD56+ve/CD8Ϫve subset since the proportion of CD56+/CD8wk+ve cells was lower in the fully TCD group than in the non-TCD group initially (Figure 3d ). This NK cell subset declined in the partially and non-TCD groups with time but increased substantially in the fully TCD group such that it was significantly greater by the latter 6 months (P Ͻ 0.001). The increase of CD8wk+ve cells within the NK cell subset in the fully TCD group was accompanied by a concomitant decline in CD56+ve/ CD8Ϫve cells as shown by the increase in the proportion of CD56+ve/CD8wk+ve cells within the total CD56 cell subset (Figure 3d ) without a substantial increase in the total proportion of NK cells (Figure 3c ).
The percentage of CD56+ve/CD8wk+ve cells as a proportion of the total NK cell subset fell in the non-TCD group with progression from BMT, although their absolute number increased due to the increasing absolute lymphocyte count. In contrast, recipients of either partial or fully TCD BMT showed a constant rise in both absolute number (Figure 3b ) and in relative proportion (Figure 3d ). In the partial TCD group this was due to a preferential loss of CD56 + /CD8Ϫve cells since the total proportion of NK cells fell during the same period (Figure 3c ).
Discussion
We and others have previously described the patterns of cellular and humoral immune reconstitution after TCD BMT 10, 11, 14, 15 including functional studies. 9, [16] [17] [18] Two published studies have involved recipients of Campath-1M-treated bone marrows 11, 15 but this is the first to analyse the effect of returning differing numbers of T cells with the graft. Furthermore, the use of three-colour immunophenotyping has allowed greater dissection of the cell subsets of interest than previously possible.
In common with Foot et al 15 and Keever et al 18 we found that lymphocyte engraftment was broadly similar after depleted and non-depleted grafts although our group of fully TCD patients did show significantly poorer lymphocyte recovery in the latter 6 months of study. Our observation that CD4 cell recovery was considerably slower after either partial or full TCD and that this was far more prolonged than CD8 cells was also in keeping with the results of Foot and colleagues.
The differential emergence of CD45RA + CD4 cells in the three groups of patients is of note, particularly in comparison with the dynamics of CD45RA + CD8 cell repopulation. CD45RA is a marker of naive T cells 19 and the appearance of CD4 cells expressing this antigen in patients after allogeneic BMT implies that donor-derived immature cells are involved in the repopulation of the immune system. However, it is intriguing that recipients of non-TCD grafts showed consistently higher ratios of CD45RA + :CD45RO Ϫ CD4 cells than did recipients of TCD grafts. One might expect T cell repopulation to be faster in recipients of non-TCD grafts since donor T cells will have been transferred with the graft. Indeed, Roux et al 11 showed that the T cell repertoire of recipients of TCD transplants was extremely restricted whereas patients who received non-TCD grafts showed broad T cell repopulation. They concluded from this that early T cell reconstitution after allogeneic transplant is due to peripheral expansion of T cells present in the stem cell graft although a late wave of increased diversity was observed in a proportion of patients. Our data show that naive CD4 cells appear early after both TCD and T cell replete transplantation and their relative proportion within the CD4 subset increases substantially in recipients of T cell-replete grafts while declining in recipi-ents of fully TCD grafts. The Roux data showed that host T cells survived in the recipients of TCD transplants for up to 6 months. If this is the case in our patients, then the CD45RA + cells in the recipients of fully TCD grafts may have been of host origin and their subsequent loss due to the expanding donor T cell pool.
However, this is difficult to reconcile with the CD8 reconstitution data in which the fully TCD recipients showed a consistent expansion of CD45RA + cells in common with the non-and partial TCD grafts. Our current interpretation of these results is that naive CD4 and CD8 cells are generated after T cell-depleted or -replete transplants from donor-derived lymphocyte precursors and these cells mature either in the residual host thymus or via extrathymic pathways such as the gut-associated lymphoid tissue. 12 The differences between our results and those of Roux et al may be due to the additional GVHD prophylaxis with cyclosporin A and methotrexate which was given to their patients.
With regard to CD8 T cell reconstitution we observed rapid reconstitution to normal proportions in all patient groups although the fully TCD grafts were associated with a slightly slower recovery. In keeping with previous results from studies of TCD BMT recipients, we saw no evidence of a CD8 'overshoot' beyond normal levels. 14, 15, 18 However, neither did we observe this in the recipients of non-TCD transplants although it has been reported previously. 20, 21 We did observe very high levels of activation in the CD8 subset irrespective of T cell depletion and the majority of these cells expressed CD57. High levels of activated CD8 cells and the expansion of the CD57 + subset after BMT have been reported before 14 and it was suggested that this may be associated with cytomegalovirus infection. We found that increased incidence of HLA-DR and CD57 expression on CD8 cells was universal among our patients and thus we could not associate it with CMV. It may reflect the interplay between donor immune system and the allogeneic host environment in the establishment of peripheral tolerance.
One of the most consistent findings in studies of TCD and non-TCD stem cell transplantation is the early and rapid expansion of natural killer cell subsets. We and others have shown previously that these cells are functional 16, 18 and that they can mediate anti-leukaemia activity. 22 In this study we show that this NK cell recovery is equivalent in both TCD and non-TCD groups and that relative expansion is faster in recipients of fully TCD grafts. Furthermore, it is sustained for a longer period in recipients of fully TCD grafts than in either non-or partially TCD transplant groups. In a similar group of patients receiving autologous BMT for acute leukaemia we have shown specific anti-leukaemia cytotoxicity mediated by NK cells post transplant. 23 This activity was greatest within the CD56 + /CD8wk + cells. In this study we have shown that CD56 + /CD8wk + cells are present in all three groups of patients although their incidence is highest in the recipients of fully TCD grafts. This may be significant in the low relapse rate observed in our unit despite the long-term use of TCD as GVHD prophylaxis without additional immunosuppression. 7 T cell depletion in allogeneic stem cell transplantation is currently seeing a revival in HLA-matched unrelated and HLA-mismatched related donor transplants where it appears to be the optimal GVHD prophylaxis. Indeed, in many groups such as ours, it is used in early disease (AML/ALL, CR1; CML, CP) where prevention of acute and chronic GVHD is almost complete even in the absence of post-transplant immune suppression. We have previously demonstrated that it can be used safely with low incidence of graft rejection and of leukaemia relapse but the issue of post transplant immune responsiveness has remained a source of concern. Here we have shown that CD8 T cell and NK cell reconstitution is rapid after Campath-1M-depleted allografting although CD4 repopulation is severely delayed even after partial TCD of the graft. Despite this, naive CD4 cells are present in the peripheral blood of patients after TCD grafts and these may ultimately contribute to a normal T cell repertoire.
The advantage of Campath-1M plus autologous complement for ex vivo TCD is that the degree of TCD can be regulated, which we believe is important in maintaining the balance between graft rejection, GVHD and GVL. It must be remembered that laboratory tests of lymphocyte subset recovery are simply markers of an in vivo phenomenon and the real test of immune reconstitution is the clinical outcome of the transplant. We have not observed a higher incidence of fatalities due to infectious disease in our fully or partial TCD graft recipients as compared with our non-TCD patients and are confident that the use of Campath-1M for ex vivo TCD at the levels used here is a safe alternative to post transplant immunosuppression. The high survival rates in the recipients of partial and fully TCD grafts (Table 1) are testaments to the success of this strategy in prevention of GVHD while maintaining the GVL effect.
